Signal transduction in ischemic preconditioning: The role of kinases and mitochondrial K(ATP) channels

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 5, 1999, Pages 741-754

  Baines, Christopher P ^a   Cohen, Michael V ^a   Downey, James M ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Adenosine; Ischemic preconditioning; K(ATP) channels; Mitogen activated protein kinase; Protein kinase C; Tyrosine kinase

Indexed keywords

ADENOSINE; BRADYKININ; OPIATE DERIVATIVE; OXYGEN RADICAL; POTASSIUM CHANNEL; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CHANNEL GATING; ENZYME ACTIVATION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032941096     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00251.x     Document Type: Article

References (111)

1. 1. Downey JM, Cohen MV: Signal transduction in ischemic preconditioning. Z Kardiol 1995;84(Suppl 4):77-86.
2. 2. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
3. 3. Liu Y, Downey JM: Ischemic preconditioning protects against infarction in rat heart. Am J Physiol 1992;263: H1107-H1112.
4. 1 adenosine receptors in rabbit heart. Circulation 1991;84:350-356.
5. 5. Vahlhaus C, Schulz R, Post H, et al: No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res 1996;79:407-414.
6. + channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995;77:1030-1035.
7. 7. Ikonomidis JS, Shirai T, Weisel RD, et al: Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. Am J Physiol 1997; 272:H1220-H1230.
8. 8. Shiki K, Hearse DJ: Preconditioning of ischemic myocardium: Reperfusion-induced arrhythmias. Am J Physiol 1987;253:H1470-H1476.
9. 9. Vegh A, Szekeres L, Parratt J: Preconditioning of the ischaemic myocardium; Involvement of L-arginine nitric oxide pathway. Br J Pharmacol 1992;107:648-652.
10. 10. Vegh A, Papp JG, Szekeres L, et al: The local intracoronary administration of methylene blue prevents the pronounced antiarrhythmic effect of ischaemic preconditioning. Br J Pharmacol 1992;107:910-911.
11. 11. Cohen MV, Yang X-M, Downey JM: Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. Circ Res 1994;74:998-1004.
12. 12. Van Winkle DM, Thornton JD, Downey DM, et al: The natural history of preconditioning: Cardioprotection depends on duration of transient ischemia and time to subsequent ischemia. Coron Art Dis 1991;2:613-619.
13. 13. Deutsch E, Berger M, Kussmaul WG, et al: Adaptation to ischemia during percutaneous transluminal coronary angioplasty: Clinical, hemodynamic, and metabolic features. Circulation 1990;82:2044-2051.
14. 14. Yang X-M, Baxter GF, Heads RJ, et al: Infarct limitation of the second window of protection in a conscious rabbit model. Cardiovasc Res 1996;31:777-783.
15. 1-selective adenosine analogues protects the heart against infarction. Circulation 1992; 85:659-665.
16. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994;28:1057-1061.
17. 6-(3-iodobenzyl) adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997;80: 800-809.
18. ATP channels, and ischemic preconditioning in dogs. Am J Physiol 1993;264:H1327-H1336.
19. 19. Schulz R, Rose J, Post H, et al: Involvement of endogenous adenosine in ischaemic preconditioning in swine. Pflügers Arch 1995;430:273-282.
20. ATP channel. Am J Physiol 1994;266:H829-H839.
21. 21. Walker DM, Walker JM, Pugsley WB, et al: Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol 1995;27:1349-1357.
22. 22. Headrick JP: Ischemic preconditioning: Bioenergetic and metabolic changes and the role of endogenous adenosine. J Mol Cell Cardiol 1996;28:1227-1240.
23. 23. Thornton JD, Thornton CS, Downey JM: Effect of adenosine receptor blockade: Preventing protective preconditioning depends on time of initiation. Am J Physiol 1993;265:H504-H508.
24. 24. Kitakaze M, Hori M, Morioka T, et al: Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosine release. Circulation 1994;89:1237-1246.
25. 25. Goto M, Cohen MV, Van Wylen DGL, et al: Attenuated purine production during subsequent ischemia in preconditioned rabbit myocardium is unrelated to the mechanism of protection. J Mol Cell Cardiol 1996;28: 447-454.
26. 26. Iliodromitis EK, Miki T, Liu GS, et al: The PKC activator PMA preconditions rabbit heart in the presence of adenosine receptor blockade: Is 5′-nucleotidase important? J Mol Cell Cardiol 1998;30:2201-2211.
27. 27. Silva PH, Dillon D, Van Wylen DGL: Adenosine deaminase inhibition augments interstitial adenosine but does not attenuate myocardial infarction. Cardiovasc Res 1995;29:616-623.
28. 28. Goto M, Liu Y, Yang X-M, et al: Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995;77:611-621.
29. 29. Schultz JEJ, Hsu AK, Gross GJ: Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996;78:1100-1104.
30. 30. Miki T, Cohen MV, Downey JM: Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol Cell Biochem 1998; 186:3-12.
31. 31. Baines CP, Goto M, Downey JM: Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 1997;29:207-216.
32. 1 receptor activation is abolished by protein kinase C inhibitors in the rabbit. Cardiovasc Res 1995;29:682-688.
33. 1-Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res 1994;75:576-585.
34. 34. Wang P, Gallagher KP, Downey JM, et al: Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart. J Mol Cell Cardiol 1996;28:579-588.
35. 35. Liu Y, Tsuchida A, Cohen MV, et al: Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995;27:883-892.
36. 36. Ping P, Zhang J, Qiu Y, et al: Ischemic preconditioning induces selective translocation of protein kinase C isoforms ε and η in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res 1997;81:404-414.
37. 37. Mochly-Rosen D, Gordon AS: Anchoring proteins for protein kinase C: A means for isozyme selectivity. FASEB J 1998;12:35-42.
38. 38. Jaken S: Protein kinase C isozymes and substrates. Curr Opin Cell Biol 1996;8:168-173.
39. 39. Ytrehus K, Liu Y, Downey JM: Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994;266:H1145-H1152.
40. 40. Mitchell MB, Meng X, Ao L, et al: Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res 1995;76:73-81.
41. 41. Liu Y, Cohen MV, Downey JM: Chelerythrine, a highly selective protein kinase C inhibitor, blocks the antiinfarct effect of ischemic preconditioning in rabbit hearts. Cardiovasc Drugs Ther 1994;8:881-882.
42. 42. Speechly-Dick ME, Mocanu MM, Yellon DM: Protein kinase C: Its role in ischemic preconditioning in the rat. Circ Res 1994;75:586-590.
43. 43. Przyklenk K, Sussman MA, Simkhovich BZ, et al: Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation 1995; 92:1546-1557.
44. 44. Kitakaze M, Node K, Minamino T, et al: Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5′-nucleotidase. Circulation 1996;93:781-791.
45. 45. Vahlhaus C, Schulz R, Post H, et al: Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol 1998;30:197-209.
46. 46. Yang X-M, Sato H, Downey JM, et al: Protection of ischemic preconditioning is dependent upon a critical timing sequence of protein kinase C activation. J Mol Cell Cardiol 1997;29:991-999.
47. 47. Gray MO, Karliner JS, Mochly-Rosen D: A selective ε-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem 1997;272:30945-30951.
48. 48. Liu Y, Ytrehus K, Downey JM: Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol 1994;26:661-668.
49. 49. Armstrong SC, Hoover DB, Delacey MH, et al: Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes. J Mol Cell Cardiol 1996;28:1479-1492.
50. 50. Liu GS, Mochly-Rosen D, Cohen MV, et al: Protein kinase C-ε, not δ, is responsible for the protection of preconditioning in rabbit cardiomyocytes. (Abstract) Circulation 1998;98(Suppl I):I-71.
51. 51. Wilson S, Song W, Karoly K, et al: Delayed cardioprotection is associated with the subcellular relocalization of ventricular protein kinase Cε, but not p42/ 44MAPK. Mol Cell Biochem 1996;160/161:225-230.
52. 52. Cantley LC, Auger KR, Carpenter C, et al: Oncogenes and signal transduction. Cell 1991;64:281-302.
53. 53. Horrigan MCG, MacIsaac AI, Nicolini FA, et al: Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation 1996;94:1927-1933.
54. 54. Htun P, Ito W, Kirsch K-P, et al: aFGF induced cardioprotection in ischemic myocardium can be antagonized by suramin. (Abstract) Circulation 1996;94(Suppl I):I-607.
55. 55. Vogt AM, Htun P, Kluge A, et al: Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery occlusion. Cardiovasc Res 1997;33: 469-477.
56. 56. Buerke M, Murohara T, Skurk C, et al: Cardioprotective effect of insulin-like growth factor-I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A 1995;92:8031-8035.
57. 57. Baines CP, Wang L, Downey JM, et al: Cardioprotection by insulin is dependent on phosphatidylinositol 3-kinase but not protein kinase C. (Abstract) Circulation 1997;96(Suppl I):I-573-I-574.
58. 58. Seger R, Biener Y, Feinstein R, et al: Differential activation of mitogen-activated protein kinase and S6 kinase signaling pathways by 12-O-tetradecanoylphorbol-13-acetate (TPA) and insulin: Evidence for involvement of a TPA-stimulated protein-tyrosine kinase. J Biol Chem 1995;270:28325-28330.
59. 59. Ogawa W, Hosomi Y, Roth RA: Activation of protein kinase C stimulates the tyrosine phosphorylation and guanosine triphosphatase-activating protein association of P60 in rat hepatoma cells. Endocrinology 1995;136: 476-481.
60. 60. Offermanns S, Bombien E, Schultz G: Stimulation of tyrosine phosphorylation and mitogen-activated-protein (MAP) kinase activity in human SH-SY5Y neuroblastoma cells by carbachol. Biochem J 1993;294:545-550.
61. 61. Khalil RA, Menice CB, Wang C-LA, et al: Phosphotyrosine-dependent targeting of mitogen-activated protein kinase in differentiated contractile vascular cells. Circ Res 1995;76:1101-1108.
62. 62. Maulik N, Watanabe M, Zu Y-L, et al: Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase two in rat hearts. FEBS Lett 1996; 396:233-237.
63. 63. Baines CP, Wang L, Cohen MV, et al: Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J Mol Cell Cardiol 1998;30:383-392.
64. 64. Kitakaze M, Node K, Funaya H, et al: Tyrosine kinase is not involved in the infarct size limiting effects of ischemic preconditioning in the canine heart. (Abstract) Circulation 1997;96(Suppl I):I-574.
65. 65. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186.
66. 66. Sugden PH, Bogoyevitch MA: Intracellular signalling through protein kinases in the heart. Cardiovasc Res 1995;30:478-492.
67. 67. Raingeaud J, Gupta S, Rogers JS, et al: Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995;270:7420-7426.
68. 68. Sugden PH, Clerk A: "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998;83:345-352.
69. 69. Clerk A, Fuller SJ, Michael A, et al: Stimulation of "stress-regulated" mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J Biol Chem 1998;273:7228-7234.
70. 2-terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 and 3: MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo. J Biol Chem 1997;272:14489-14496.
71. 71. Foltz IN, Gerl RE, Wieler JS, et al: Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly conserved c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) activated by environmental stresses and physiological stimuli. J Biol Chem 1998; 273:9344-9351.
72. q/11,-induced activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. J Biol Chem 1998;273:22892-22898.
73. 73. Cuenda A, Dorow DS: Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1. Biochem J 1998;333:11-15.
74. 74. Zanke BW, Rubie EA, Winnett E, et al: Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator complexes. J Biol Chem 1996;271:29876-29881.
75. 75. Freshney NW, Rawlinson L, Guesdon F, et al: Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of hsp27. Cell 1994;78: 1039-1049.
76. 76. Guay J, Lambert H, Gingras-Breton G, et al: Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J Cell Sci 1997;110:357-368.
77. 77. Martin JL, Mestril R, Hilal-Dandan R, et al: Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 1997;96:4343-4348.
78. 78. Kim SO, Salh B, Pelech SL, et al: Activation of MAPKAP kinase-2 by adenosine in rat heart. J NIH Res 1997;9(1):54.
79. 79. Trammell BW, Pain S, Downey JM, et al: MAPKAPK2 is activated in preconditioned rabbit heart. (Abstract) J Mol Cell Cardiol 1998;30:A265.
80. 80. Weinbrenner C, Liu G-S, Cohen MV, et al: Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 1997;29:2383-2391.
81. ATP channels and actin cytoskeleton. Am J Physiol 1999; (in press).
82. 82. Cuenda A, Rouse J, Doza YN, et al: SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229-233.
83. 83. Clerk A, Sugden PH: The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 1998;426:93-96.
84. 84. Barancik M, Htun P, Maeno Y, et al: Differential regulation of distinct protein kinase cascades by ischemia and ischemia/reperfusion in porcine myocardium. (Abstract) Circulation 1997;96(Suppl I):I-252.
85. 85. Htun P, Barancik M, Maeno Y, et al: Stimulation of stress activated protein kinases by anisomycin protects ischemic myocardium. (Abstract) Circulation 1997; 96(Suppl I):I-252.
86. +-channel. News Physiol Sci 1997;12:255-263.
87. ATP channels. Physiol Rev 1998;78:227-245.
88. ATP) openers in models of myocardial ischemia and reperfusion. Can J Physiol Pharmacol 1997; 75:309-315.
89. 89. Thornton JD, Thornton CS, Sterling DL, et al: Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts. Circ Res 1993;72:44-49.
90. ATP channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res 1994;28:1337-1341.
91. 91. Hide EJ, Thiemermann C: Limitation of myocardial infarct size in the rabbit by ischaemic preconditioning is abolished by sodium 5-hydroxydecanoate. Cardiovasc Res 1996;31:941-946.
92. ATP) channels. (Abstract) J Mol Cell Cardiol 1995;27:A142.
93. 93. Gross GJ, Auchampach JA: Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-233.
94. 94. Auchampach JA, Grover GJ, Gross GJ: Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 1992;26:1054-1062.
95. 95. Schulz R, Rose J, Heusch G: Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994;267:H1341-H1352.
96. ATP channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart. J Mol Cell Cardiol 1997;29:1055-1060.
97. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769-1775.
98. ATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol 1995;26:145-152.
99. 99. Armstrong SC, Liu GS, Downey JM, et al: Potassium channels and preconditioning of isolated rabbit cardiomyocytes: Effects of glyburide and pinacidil. J Mol Cell Cardiol 1995;27:1765-1774.
100. 100. Grover GJ, D'Alonzo AJ, Hess T, et al: Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening. Cardiovasc Res 1995;30:731-738.
101. 101. McCullough JR, Normandin DE, Conder ML, et al: Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res 1991;69:949-958.
102. + channels: Possible mechanism of cardioprotection. Circ Res 1997; 81:1072-1082.
103. 103. Liu Y, Sato T, O'Rourke B, et al: Mitochondrial ATP-dependent potassium channels: Novel effectors of cardioprotection? Circulation 1998;97:2463-2469.
104. 104. Garlid KD: Cation transport in mitochondria - the potassium cycle. Biochim Biophys Acta 1996;1275:123-126.
105. 105. Cribier A, Korsatz L, Koning R, et al: Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: A prospective study. J Am Coll Cardiol 1992;20:578-586.
106. 106. Shattock MJ, Lawson CS, Hearse DJ, et al: Electrophysiological characteristics of repetitive ischemic preconditioning in the pig heart. J Mol Cell Cardiol 1996;28:1339-1347.
107. 107. Cohen MV, Yang X-M, Downey JM: Attenutation of S-T segment elevation during repetitive coronary occlusions truly reflects the protection of ischemic preconditioning and is not an epiphenomenon. Basic Res Cardiol 1997;92:426-434.
108. + channel blocker. Circulation 1994;90:700-705.
109. 109. Leesar MA, Stoddard M, Ahmed M, et al: Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997;95:2500-2507.
110. 110. Libby P, Maroko PR, Covell JW, et al: Effect of practolol on the extent of myocardial ischaemic injury after experimental coronary occlusion and its effects on ventricular function in the normal and ischaemic heart. Cardiovasc Res 1973;7:167-173.
111. 111. Maroko PR, Radvany P, Braunwald E, et al: Reduction of infarct size by oxygen inhalation following acute coronary occlusion. Circulation 1975;52:360-368.